Sanofi India Declares ₹75 Interim Dividend; Q3 PAT Up 54%

Sanofi India Limited announced its unaudited financial results for the quarter and nine months ended September 30, 2026. The company reported domestic net sales growth of 2% and total net sales growth of 4% compared to Q3 2025. The Insulin portfolio showed strong performance with 9% growth. Profits before tax and exceptional items rose to INR 158 crores from INR 130 crores in Q3 2025, with profit before tax as a percentage of net sales improving to 34%. The Board of Directors declared an interim dividend of ₹75 per equity share and set November 5, 2026, as the record date. The company also highlighted its CSR initiatives, including the KiDS Program and Medical Mobile Units.